Great Basin Scientific Inc (NASDAQ:GBSN), a molecular diagnostics company, today announced it has initiated a clinical trial for its sample-to-result Bordatella Direct Test, which will detect, directly from patient specimen, Bordatella pertussis, a bacteriumcausing a highly contagious respiratory disease commonly known as whooping cough. This is the first of five clinical trials the Company plans to initiate in 2016.

“As we’ve committed to our customers and stockholders, 2016 is going to be a time of continued R&D progress and customer growth for Great Basin,” said Ryan Ashton, co-founder and Chief Executive Officer of Great Basin Scientific. “The on-time start of the clinical trial for our Bordatella Direct Test is indicative of our commitment to delivering on our menu targets and represents Great Basin’s dedication to meeting strategic objectives.”

Great Basin intends to submit its 510(K) Clearance application for the Bordatella Direct Test to the U.S. Food & Drug Administration (FDA) in the fourth quarter of this year, on-track with guidance previously issued by the Company.(Original Source)

Shares of Great Basin Scientific are currently trading at $1.92, up $0.12 or 6.67%. GBSN has a 1-year high of $10164 and a 1-year low of $1.77. The stock’s 50-day moving average is $3.60 and its 200-day moving average is $55.68.

Great Basin Scientific, Inc. is a molecular diagnostic testing company, which focused on the development and commercialization of its patented, molecular diagnostic platform designed to test for infectious disease, especially hospital-acquired infections. Great Basin Scientific was founded by David C. Ward, Anthony R. Torres and David Spafford on June 27, 2003 and is headquartered in Salt Lake City, UT.